XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 13, 2016 and accepted by EDGAR at May 13, 2016, 17:15 ET.
Management's discussion and analysis
As filed, 19,718 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of different diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization technologies or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While primarily focused on bringing our lead product candidate to market, we have also developed a proprietary True Human™ monoclonal antibody discovery platform and manufacturing system.
We have never been profitable and, as of March 31, 2016, we had an accumulated deficit of $140.9 million. We had net losses of $10.3 and $8.1 million for three months ended March 31, 2016 and 2015, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and begin to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of March 31, 2016, we had 83 employees.
Recent Events:
Clinical trial and construction of the new manufacturing facility Highlights
As of March 2016, XBiotech has achieved significant milestones with it's Xilonix™ and 514G3 programs. Enrollment on a Phase III Symptomatic Colorectal Cancer Study has been completed, with enrollment of 335 subjects. Because the study endpoints were satisfactorily met, XBiotech decided to proceed with the submission of a Marketing Authorization Application to the European Medicines Agency, and possibly other foreign regulatory authorities. Additionally, the Staphylococcus Aureus Bacteremia Phase I and II Study with a brand new antibody therapy, 514G3, has completed enrollment for Phase I. Phase II commenced once it was established that there were no dose-related toxicities in Phase I.
There was significant progress in the Q1 2016 with regard to construction of the new manufacturing facility located in Austin Texas. During the Quarter the build out of the interior administrative and lab spaces continued. Installation of HVAC equipment and duct work, ceiling and wall panels as part of the clean room construction activities also progressed. Construction of utility systems to support manufacturing, including electrical, the purified water system, and gas distribution systems began in Q1 and is progressing on schedule. While construction has moved forward significantly, additional delays due to long lead time equipment procurement have been incurred. XBiotech now anticipates final building completion in the August 2016 time frame with plant shakedown and validation starting immediately thereafter. We should begin producing antibody to support registration of the new facility late in Q3 2016.
Revenues
To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.
Research and Development Expenses
Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.
Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2016, we have recorded total research and development expenses, including share-based compensation, of $108.9 million. Our total research and development expenses for the three months ended March 31, 2016 and 2015 were $7.8 million and $6.8 million, respectively. Share-based compensation accounted for $0.6 million and $0.5 million for the three months ended March 31, 2016 and 2015, respectively.
Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2016 and 2015 were 76% and 83%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2016 and 2015, were 86% and 91%, respectively.
As planned, our clinical costs have increased as we advanced Xilonix™ as an anti-cancer therapy for treating last-line metastatic colorectal cancer, under a regulatory pathway through Phase III clinical trials in the US, Europe, Australia and Israel. We will further expand the studies to South America and Canada, with all territories expected to be active during Q2 2016. Our clinical study underway in Europe, that is regulated by the European Medicines Agency (EMA), completed enrollment in November, 2015. The submission for marketing approval to the EMA was completed in March 2016 which could position the Company to generate related revenues in 2017 if it receives EMA marketing approval and the Company successfully completes its commercialization plan for Xilonix™.
The clinical research and development costs will also increase as we have launched a Phase I and II clinical study of novel True Human™ therapeutic antibody for treating serious infections due to Staphylococcus aureus in the U.S. We expect to complete expansion of this study into Europe, South Korea and Taiwan for participation in the Phase II portion by the end of Q3 2016.
The Company’s plans to pursue an advanced regulatory path for Pyoderma Gangrenosum is on hold indefinitely while we await the outcome of other programs in later stages of development. In the meantime, based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success as well as commercial potential. For R&D candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.
Due to the fact that our drug candidates are in the early stage of development, we cannot estimate anticipated completion dates and when we might receive material net cash inflows from our research and development projects.
General and Administrative Expenses
General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2016 and 2015 were $2.4 million and $1.4 million, respectively. Share-based compensation accounted for $1.2 million and $0.8 million for the three months ended March 31, 2016 and 2015, respectively.
Critical Accounting Policies
Our Management’s Discussion and Analysis of our Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States, or US GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.
We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in the notes to our financial statements appearing in this prospectus, we believe that the following accounting policies are the most critical to understanding and evaluating our reported financial results.
Stock-Based Compensation
Stock-based awards are measured at fair value at each grant date. We recognize stock-based compensation expenses ratably over the requisite service period of the option award.
Determination of the Fair Value of Stock-Based Compensation Grants
The determination of the fair value of stock-based compensation arrangements is affected by a number of variables, including estimates of the fair value of our common stock, expected stock price volatility, risk-free interest rate and the expected life of the award. We value stock options using the Black-Scholes option-pricing model, which was developed for use in estimating the fair value of traded options that are fully transferable and have no vesting restrictions. Black-Scholes and other option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. If we made different assumptions, our stock-based compensation expenses, net loss, and net loss per common share could be significantly different. Prior to our IPO in April 2015, we issued common stock for cash consideration to new investors. We believe that such transactions represent the best evidence of fair value of our common stock. Therefore, we used the sales price of our common stock during the three months ended March 31,2015 as the fair value of our common stock.
The following summarizes the assumptions used for estimating the fair value of stock options granted during the periods indicated:
| Three Months Ended March 31, 2016 | 2015 | |||||
|---|---|---|---|---|---|---|
| Dividend yield | - | - | ||||
| Expected volatility | 65% | - | 68% | 68% | ||
| Risk-free interest rate | 1.31% | - | 1.82% | 1.39% | - | 2.12% |
| Expected life (in years) | 5 | - | 10 | 5 | - | 10 |
| Weighted-average grant date fair value per share | $8.01 | $9.56 |
We have assumed no dividend yield because we do not expect to pay dividends in the foreseeable future, which is consistent with our past practice. The risk-free interest rate assumption is based on observed interest rates for U.S. Treasury securities with maturities consistent with the expected life of our stock options. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method when the stock option includes “plain vanilla” terms. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the agreement term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options. For stock options that did not include “plain vanilla” terms we used the contractual life of the stock option as the expected life. Such stock options consisted primarily of options issued to our board of directors that were immediately vested at issuance. Expected volatility is based on historical volatilities for publicly traded stock of comparable companies over the estimated expected life of the stock options.
We based our estimate of pre-vesting forfeitures, or forfeiture rate, on historical forfeiture rates. We apply the estimated forfeiture rate to the total estimated fair value of the awards, as derived from the Black-Scholes model, to compute the stock-based compensation expenses, net of pre-vesting forfeitures, to be recognized in our consolidated statements of operations.
Results of Operations
Revenue
We did not record any revenue during the three months ended March 31, 2016 and 2015.
Expenses
Research and Development
Research and Development costs are summarized as follows (in thousands):
| Three Months Ended March 31, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $1,858 | $1,430 | $428 | 30% |
| Laboratory and manufacturing supplies | 776 | 1,335 | (559) | (42%) |
| Clinical trials and sponsored research | 3,656 | 2,689 | 967 | 36% |
| Stock-based compensation | 597 | 456 | 141 | 31% |
| Other | 925 | 874 | 51 | 6% |
| Total | $7,812 | $6,784 | $1,028 | 15% |
We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.
Research and development expenses increased by $10.0 million to $7.8 million for the three months ended March 31, 2016, compared to $6.8 million for the three months ended March 31, 2015. This increase was principally due to a $10.0 million increase in clinical trial activities mainly in Europe and the US. Labor costs also increased due to the increase of current employee’s salaries and increase in the size of the workforce from 39 to 75.
General and Administrative
General and administrative costs are summarized as follows (in thousands):
| Three Months Ended March 31, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Salaries and related expenses | $527 | $199 | $328 | 165% |
| Patent filing expense | 146 | 227 | (81) | (36%) |
| Stock-based compensation | 1,219 | 767 | 452 | 59% |
| Professional fees | 92 | 132 | (40) | (30%) |
| Other | 452 | 96 | 356 | 371% |
| Total | $2,436 | $1,421 | $1,015 | 71% |
20
General and administrative expense increased by $1.0 million to $2.4 million for the three months ended March 31, 2016, compared to $1.4 million for the three months ended March 31, 2015. The increase was primarily related to increase in stock–based compensation expenses of $0.5 million, due to the grant of stock options to board members in 2016 that were immediately vested. The increase is also due to higher salaries and related expenses in 2016 because of the growing size of our workforce and a $135,100 bonus payment to an executive officer in March 2016.
Other income
The following table summarizes other income (in thousands):
| Three Months Ended March 31, 2016 | 2015 | |
|---|---|---|
| Foreign exchange gain | $(9) | $91 |
| Total | $(9) | $91 |
Other income consists primarily of a $9 thousand loss for the three months ended March 31, 2016 compared to a $91 thousand gain for the three months ended March 31, 2015.
Liquidity and Capital Resources
Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.
Since our inception on March 22, 2005 through March 31, 2016, we have funded our operations principally through the private placement of equity securities, which have provided aggregate cash proceeds of approximately $221.0 million. The following table summarizes our sources and uses of cash (in thousands):
| Net cash (used in) provided by: | Three Months Ended March 31, 2016 | 2015 |
|---|---|---|
| Operating activities | $(9,947) | $(6,531) |
| Investing activities | (2,917) | (571) |
| Financing activities | - | 2,107 |
| Effect of foreign exchange rate on cash and cash equivalents | 38 | (98) |
| Net change in cash and cash equivalents | $(12,826) | $(5,093) |
During the three months ended March 31, 2016 and 2015, our operating activities used net cash of $9.9 million and $6.5 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the three months ended March 31, 2016 as compared to the three months ended March 31, 2015 was due to increases in clinical trial activities in Europe and the US and the labor cost.
During the three months ended March 31, 2016 and 2015, our investing activities used net cash of $2.9 million and $0.6 million, respectively. We spent approximately $2.6 million more on the construction of new facilities during the three months ended March 31, 2016 compared to the three months ended March 31, 2015.
During the three months ended March 31, 2015, our financing activities provided net cash proceeds of $2.1 million and no cash provided in the three months ended March 31, 2016. During the three months ended March 31, 2015, we received requests from investors for the exercise of warrants to purchase a total of 164,999 shares of common stock at $15.00 per share for a total of approximately $2.4 million in net proceeds, and we also incurred deferred offering costs of $712 thousand, which consist of direct incremental legal, accounting and other professional service fees related to our IPO. In January 2015, we received the previously outstanding subscription receivable in the amount of $410 thousand.
We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the FDA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2016, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $78.2 million.
Contractual Obligations and Commitments
On January 12, 2008, we entered a lease agreement to lease our facility in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2014, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. Rent expense was $179 thousand and $105 thousand for the three months ended March 31, 2016 and 2015, respectively. On February 28, 2015, we extended the lease for another 4 years. The future minimum lease payments are as follows as of March 31, 2016 (in thousands):
| Contractual Obligations | Total | Less than 1 Year | 1 - 3 Years | More than 3 years |
|---|---|---|---|---|
| Operating facility leases | $1,348 | $452 | $896 | $— |
| Total contractual obligations | $1,348 | $452 | $896 | $— |
Off-Balance Sheet Arrangements
Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.
Market risk
As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.
Controls and procedures
As filed, 1,804 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management's Evaluation of our Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the first quarter of the year ended December 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Risk factors
As filed, 837 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2015. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2016-01-01 to 2016-03-31 | $7.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-01-01 to 2016-03-31 | −$10.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-01-01 to 2016-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-01-01 to 2016-03-31 | −$10.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2016-01-01 to 2016-03-31 | −$9.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2016-01-01 to 2016-03-31 | $1.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-03-31 | $78.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $79.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $101.3m | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $6.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $6.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-03-31 | $94.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-16-010052. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.